The Role of Metabolic Syndrome Components in Sensorineural Hearing Loss in Adolescents: A Case-Control Study

Jalali, Mir Mohammad; Dalili, Setila; Koohmanaee, Shahin; Rad, Samira Saee

doi:10.1055/s-0041-1742241

Cited by 1 publication

(1 citation statement)

References 51 publications

(63 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Metabolic syndrome and its associated components have the potential to lead to several comorbidities, one of which is inner ear dysfunction. The exact mechanism linking metabolic syndrome and hearing loss is not yet clear, but there is evidence that it may be related to peripheral blood vessel dysfunction [36]. It is known that subjects with metabolic syndrome had significantly higher plasma fibrinogen and homocysteine levels than subjects without metabolic syndrome.…”

Section: Metabolic Syndrome (Mets)mentioning

confidence: 99%

The Role of Fibrinogen, Homocysteine and Metabolic Syndrome’s Alterations in Sudden Sensorineural Hearing Loss (SSHL): A Narrative Review

Monzani,

Liberale,

Segato

et al. 2023

Medicina

View full text Add to dashboard Cite

Fibrinogen and homocysteine (HCY) are molecules known to play a role in vascular homeostasis, and their blood levels are often elevated in patients with metabolic syndrome. Recent evidence suggests that sudden sensorineural hearing loss (SSHL) may have a vascular origin. This has led many authors to advocate that fibrinogen, homocysteine, and metabolic syndrome (MetS) may play a direct role in SSHL. The aim of this brief review is to examine the role and influence of these molecules and MetS on the mechanisms of SSHL. Elevated fibrinogen levels have been associated with a worse prognosis in SSHL, possibly due to increased blood viscosity and decreased blood flow. Similarly, HCY has been associated with vascular damage, particularly in hyperhomocysteinemia, although the exact association with SSHL remains controversial. MetS has been demonstrated to function both as a causative factor and as a contributor to poorer recovery in cases of SSHL. However, although some studies suggest a possible role for these biomarkers and MetS in the prognosis and treatment of SSHL, specific therapeutic and preventive strategies based solely on these factors have yet to be developed. Given their potential role in prognosis and treatment and the global epidemic of metabolic syndrome, this issue needs to be analyzed comprehensively. Thus, further quality studies need to be conducted, even though it is difficult to determine the actual impact of MetS on the development of SSHL, as it is a multifactorial disease affecting multiple organs.

show abstract

Section: Metabolic Syndrome (Mets)mentioning

confidence: 99%